Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 4

1(20.0%)

5Total

N/A(4)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05273385Not ApplicableTerminated

Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

Role: collaborator

NCT06885242Phase 4Completed

Efficacy and Safety of Cyclopentolate Microdrops for Cycloplegic Refraction in Children

Role: collaborator

NCT05274321Not ApplicableCompleted

Efficacy of the Nanodropper Device on Pupillary Dilation

Role: collaborator

NCT05844384Not ApplicableRecruiting

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

Role: collaborator

NCT05181046Not ApplicableCompleted

Evaluation of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Glaucoma Patients

Role: lead

All 5 trials loaded